| Page 221 | Kisaco Research
  • Discussing the emerging trends of women’s health education & awareness on social media.
  • How companies can best utilize social media for marketing & business opportunity.
  • Addressing misinformation, trust and health literacy impacting health & wellness decision-making.
Reproductive Health
Fertility
Digital Health

Author:

Roohi Jeelani

Chief Growth Officer
Kindbody
... read more

Roohi Jeelani

Chief Growth Officer
Kindbody

Author:

Erin Nance (@littlemissdiagnosed)

CEO
FeelBetr Health
... read more

Erin Nance (@littlemissdiagnosed)

CEO
FeelBetr Health

Author:

Julia McDowell

Venture Partner
F-Prime Capital
... read more

Julia McDowell

Venture Partner
F-Prime Capital

Author:

Tori Barnes

Vice President, Communications & Corporate Marketing
Headspace
... read more

Tori Barnes

Vice President, Communications & Corporate Marketing
Headspace
 

Paul Petraro

Director, Real World Evidence Analytics
Boehringer Ingelheim

Paul Petraro

Director, Real World Evidence Analytics
Boehringer Ingelheim

Paul Petraro

Director, Real World Evidence Analytics
Boehringer Ingelheim

Gain actionable strategies for embedding AI and large language models into portfolio decision making, accelerating timelines while ensuring data quality and compliance

Author:

Gregory Goldmacher

Assistant Vice President, Clinical Research, Head, Imaging
Merck
... read more

Gregory Goldmacher

Assistant Vice President, Clinical Research, Head, Imaging
Merck
Emerging Brand Spotlight Support Sheet

Developing a mechanistic model of IVT to include nucleation and growth of magnesium pyrophosphate crystals and subsequent agglomeration of crystals and DNA

Author:

Nathan Stover

PhD Student, Chemical Engineering
Massachusetts Institute of Technology
... read more

Nathan Stover

PhD Student, Chemical Engineering
Massachusetts Institute of Technology

Hear cross-functional perspectives on successfully implementing AI across process development teams, from aligning with quality, IT, and manufacturing to overcoming cultural and technical barriers, with a focus on driving operational efficiency and long-term value

Author:

Justin Byers

Founder and Chief Executive Officer
Axio BioPharma

Justin Byers is the Founder and Chief Executive Officer of Axio BioPharma, an AI biomanufacturing company revolutionizing how monoclonal antibodies are developed and produced. Based in Madison, Wisconsin, Axio launched in 2024 with a mission to accelerate and de-risk the development of recombinant proteins and monoclonal antibodies through AI-driven process design and U.S.-based manufacturing.

Under Justin’s leadership, Axio has pioneered a data-rich, machine learning–powered approach that reduces process development timelines from years to days unlocking faster, more cost-efficient pathways for biotech partners. He has steered the company’s rapid growth, from establishing its state-of-the-art facilities to securing strategic partnerships, including collaborations to advance next-generation drug delivery technologies.

With a background at the intersection of biomanufacturing, technology, and entrepreneurship, Justin brings a vision of scaling biologics development with speed, reliability, and accessibility. He is committed to building Axio into a trusted partner for innovators worldwide, combining scientific rigor with cutting-edge AI to bring life-changing therapies to patients faster.

... read more

Justin Byers

Founder and Chief Executive Officer
Axio BioPharma

Justin Byers is the Founder and Chief Executive Officer of Axio BioPharma, an AI biomanufacturing company revolutionizing how monoclonal antibodies are developed and produced. Based in Madison, Wisconsin, Axio launched in 2024 with a mission to accelerate and de-risk the development of recombinant proteins and monoclonal antibodies through AI-driven process design and U.S.-based manufacturing.

Under Justin’s leadership, Axio has pioneered a data-rich, machine learning–powered approach that reduces process development timelines from years to days unlocking faster, more cost-efficient pathways for biotech partners. He has steered the company’s rapid growth, from establishing its state-of-the-art facilities to securing strategic partnerships, including collaborations to advance next-generation drug delivery technologies.

With a background at the intersection of biomanufacturing, technology, and entrepreneurship, Justin brings a vision of scaling biologics development with speed, reliability, and accessibility. He is committed to building Axio into a trusted partner for innovators worldwide, combining scientific rigor with cutting-edge AI to bring life-changing therapies to patients faster.

Author:

Shruti Vij

Associate Director, Data Analytics & Modeling
(Former) Takeda
... read more

Shruti Vij

Associate Director, Data Analytics & Modeling
(Former) Takeda
  • How to mitigate inappropriate drug use and dosing risk, leveraging mechanisms like Pre-Approval Information Exchange (PIE) and PDUFA timelines to shape understanding of indication, value, and safety.
  • How to engage payers as early as phase 2 to build trust and tailor future value-based contracts, launching with outcomes-driven frameworks to support access and reimbursement.
Innovation and Investment
Healthcare Costs and Outcomes

Author:

Jim Kenney

Founder – JTKENNEY
Former Manager, Specialty and Pharmacy Contracts - Harvard Pilgrim Health Care
... read more

Jim Kenney

Founder – JTKENNEY
Former Manager, Specialty and Pharmacy Contracts - Harvard Pilgrim Health Care
 

Jim Kenney

Founder – JTKENNEY
Former Manager, Specialty and Pharmacy Contracts - Harvard Pilgrim Health Care

Jim Kenney

Founder – JTKENNEY
Former Manager, Specialty and Pharmacy Contracts - Harvard Pilgrim Health Care

Jim Kenney

Founder – JTKENNEY
Former Manager, Specialty and Pharmacy Contracts - Harvard Pilgrim Health Care
  • Elucidating how researchers are using menstrual effluent to track fertility, inflammation, and disease.
  • Consumer Adoption & Clinical Validation – The path to making menstrual-based diagnostics a mainstream health tool.
  • Investment & Industry Growth – The market potential of menstrual-based biomarkers in diagnostics and therapeutics.
Reproductive Health

Equip teams with AI tools that capture process knowledge and simulate scale-up scenarios, reducing tech transfer timelines and improving first-batch success rates - critical for aligning R&D, MSAT, and manufacturing expectations early